Nuvalent (NUVL) CFO sells at $85.17–$89.12; exercises options

Q: What insider transactions did Nuvalent (NUVL) disclose?

The CFO exercised stock options and sold shares on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 plan.

Q: How many shares did the NUVL CFO exercise and sell?

On 10/13, options for 6,875 and 13,125 shares were exercised; 20,000 shares were sold. On 10/14, 20,000 options were exercised and 20,000 shares were sold.

Q: What are the exercise prices and expirations of the options?

Options exercised carried exercise prices of $6.89 (expiring 04/29/2031) and $18.93 (expiring 01/04/2032).

Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer. On 10/13/2025 and 10/14/2025, the CFO exercised employee stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

On 10/13, options for 6,875 shares at $6.89 and 13,125 shares at $18.93 were exercised, followed by sales totaling 20,000 shares at weighted-average prices within disclosed ranges of $87.15–$89.28. On 10/14, 20,000 options at $18.93 were exercised and 20,000 shares were sold at weighted-average prices within $85.17–$89.12. Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 30,662 options remained outstanding.

Insider Trade Summary

Exercise and Sale: 40,000 shares ($2.82M approx. pre-tax spread)

Exercise and Sale 13 txns

Insider Balcom Alexandra

Role Chief Financial Officer

Sold 40,000 shs ($3.49M)

Approx. gross sale proceeds $3.49M

Approx. exercise cost $674K

Approx. pre-tax spread $2.82M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	20,000	$0.00	$0.00
Exercise	Class A Common Stock	20,000	$18.93	$379K
Sale	Class A Common Stock	12,280	$85.75	$1.05M
Sale	Class A Common Stock	5,820	$86.63	$504K
Sale	Class A Common Stock	1,700	$87.67	$149K
Sale	Class A Common Stock	200	$88.90	$18K
Exercise	Stock Option (Right to Buy)	6,875	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	13,125	$0.00	$0.00
Exercise	Class A Common Stock	6,875	$6.89	$47K
Exercise	Class A Common Stock	13,125	$18.93	$248K
Sale	Class A Common Stock	6,138	$87.90	$540K
Sale	Class A Common Stock	12,266	$88.73	$1.09M
Sale	Class A Common Stock	1,596	$89.22	$142K

Holdings After Transaction: Stock Option (Right to Buy) — 66,638 contracts (Direct); Class A Common Stock — 61,734 shares (Direct)

Footnotes (10)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.15 to $88.14, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) of this Form 4.
F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.15 to $89.14, inclusive.
F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.15 to $89.28, inclusive.
F5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.17 to $86.16, inclusive.
F6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.22 to $87.21, inclusive.
F7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.22 to $88.20, inclusive.
F8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.67 to $89.12, inclusive.
F9. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
F10. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nuvalent (NUVL) disclose?

The CFO exercised stock options and sold shares on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 plan.

How many shares did the NUVL CFO exercise and sell?

On 10/13, options for 6,875 and 13,125 shares were exercised; 20,000 shares were sold. On 10/14, 20,000 options were exercised and 20,000 shares were sold.

At what prices were the NUVL shares sold?

Sales were reported at weighted-average prices within ranges of $87.15–$89.28 on 10/13 and $85.17–$89.12 on 10/14.

What are the exercise prices and expirations of the options?

Options exercised carried exercise prices of $6.89 (expiring 04/29/2031) and $18.93 (expiring 01/04/2032).

How many NUVL shares does the CFO own after these trades?

Following the reported transactions, the CFO directly owned 61,734 Class A shares and had 30,662 options remaining.

Were these trades pre‑planned?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last)

(First)

(Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	10/13/2025		M⁽¹⁾		6,875	A	$6.89	68,609	D
Class A Common Stock	10/13/2025		M⁽¹⁾		13,125	A	$18.93	81,734	D
Class A Common Stock	10/13/2025		S⁽¹⁾		6,138	D	$87.9⁽²⁾	75,596	D
Class A Common Stock	10/13/2025		S⁽¹⁾		12,266	D	$88.73⁽³⁾	63,330	D
Class A Common Stock	10/13/2025		S⁽¹⁾		1,596	D	$89.22⁽⁴⁾	61,734	D
Class A Common Stock	10/14/2025		M⁽¹⁾		20,000	A	$18.93	81,734	D
Class A Common Stock	10/14/2025		S⁽¹⁾		12,280	D	$85.75⁽⁵⁾	69,454	D
Class A Common Stock	10/14/2025		S⁽¹⁾		5,820	D	$86.63⁽⁶⁾	63,634	D
Class A Common Stock	10/14/2025		S⁽¹⁾		1,700	D	$87.67⁽⁷⁾	61,934	D
Class A Common Stock	10/14/2025		S⁽¹⁾		200	D	$88.9⁽⁸⁾	61,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.89	10/13/2025		M⁽¹⁾			6,875	⁽⁹⁾	04/29/2031	Class A Common Stock	6,875	$0.00	35,976	D
Stock Option (Right to Buy)	$18.93	10/13/2025		M⁽¹⁾			13,125	⁽¹⁰⁾	01/04/2032	Class A Common Stock	13,125	$0.00	50,662	D
Stock Option (Right to Buy)	$18.93	10/14/2025		M⁽¹⁾			20,000	⁽¹⁰⁾	01/04/2032	Class A Common Stock	20,000	$0.00	30,662	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.15 to $88.14, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.15 to $89.14, inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.15 to $89.28, inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.17 to $86.16, inclusive.

6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.22 to $87.21, inclusive.

7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.22 to $88.20, inclusive.

8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.67 to $89.12, inclusive.

9. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

10. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR